Qiu Chen, Zhang Qiao-Hua, Wang Gang-Gang
Department of Lymphatic Oncology, Cancer Center, Shanxi Bethune Hospital, Taiyuan 030032, Shanxi Province, China.
Department of Lymphatic Oncology, Cancer Center, Shanxi Bethune Hospital, Taiyuan 030032, Shanxi Province, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Oct;30(5):1415-1422. doi: 10.19746/j.cnki.issn.1009-2137.2022.05.017.
To investigate the expression of miR-126 in diffuse large B-cell lymphoma (DLBCL) tissues and its biological function.
The lymphoma tissues of 46 DLBCL patients in our hospital were selected as the research object, and the lymph node hyperplasia tissue of 31 patients with reactive hyperplasia were selected as controls. The expression level of miR-126 in the patients' tissues was detected by real-time fluorescent quantitative PCR (RT-qPCR), and the correlation of miR-126 expression with the pathological characteristics and prognosis of the patients was analyzed. The DLBCL cell line SU-DHL-4 was transfected with miR-126 inhibitor and its negative control (NC inhibitor) or miR-126 mimics and its negative control (NC mimics). RT-qPCR assay was used to detect the expression level of miR-126 in cells; MTT method was used to detect cell proliferation activity; single clone formation test was used to detect cells colony-forming ability; Annexin V/PI double staining assay was used to detect cell apoptosis; Transwell test was used to detect cell migration and invasion ability; the expression levels of apoptosis-related proteins cleaved-Caspase-3, Bcl-2 and Bax were detected by Western blot.
miR-126 was highly expressed in lymphoma tissues of DLBCL patients, and its expression level was significantly correlated with Hans type, IPI score and Ann-Arbor stage of DLBCL patients (P<0.05). Kaplan-Meier survival analysis showed that the survival rate of DLBCL patients with high expression of miR-126 was significantly lower than that of patients with low expression (P<0.05). Compared with the NC mimics group, the miR-126 expression level, cell proliferation rate, number of colony-forming units, migration and invasion ability, and Bcl-2 protein expression level in the miR-126 mimics group were significantly increased (P<0.05), but the cells apoptotic rate, cleaved-Caspase-3 and Bax protein expression levels were significantly reduced (P<0.05). Compared with the NC inhibitor group, the miR-126 expression level, cell proliferation rate, number of colony-forming units, migration and invasion ability, and Bcl-2 protein expression level in the miR-126 inhibitor group were significantly reduced (P<0.05), but the cells apoptosis rate, cleaved-Caspase-3 and Bax protein expression levels were significantly increased (P<0.05).
miR-126 is highly expressed in lymphoma tissues of DLBCL patients and its expression level is related to the poor prognosis of patients. miR-126 can promote DLBCL cell proliferation, invasion and migration, and inhibit cell apoptosis.
探讨miR-126在弥漫性大B细胞淋巴瘤（DLBCL）组织中的表达及其生物学功能。
选取我院46例DLBCL患者的淋巴瘤组织作为研究对象，选取31例反应性增生患者的淋巴结增生组织作为对照。采用实时荧光定量PCR（RT-qPCR）检测患者组织中miR-126的表达水平，并分析miR-126表达与患者病理特征及预后的相关性。用miR-126抑制剂及其阴性对照（NC抑制剂）或miR-126模拟物及其阴性对照（NC模拟物）转染DLBCL细胞系SU-DHL-4。采用RT-qPCR法检测细胞中miR-126的表达水平；采用MTT法检测细胞增殖活性；采用单克隆形成试验检测细胞集落形成能力；采用Annexin V/PI双染法检测细胞凋亡；采用Transwell试验检测细胞迁移和侵袭能力；采用蛋白质印迹法检测凋亡相关蛋白cleaved-Caspase-3、Bcl-2和Bax的表达水平。
miR-126在DLBCL患者淋巴瘤组织中高表达，其表达水平与DLBCL患者的Hans分型、国际预后指数（IPI）评分及Ann-Arbor分期显著相关（P<0.05）。Kaplan-Meier生存分析显示，miR-126高表达的DLBCL患者生存率显著低于低表达患者（P<0.05）。与NC模拟物组相比，miR-126模拟物组的miR-126表达水平、细胞增殖率、集落形成单位数量、迁移和侵袭能力以及Bcl-2蛋白表达水平显著升高（P<0.05），但细胞凋亡率、cleaved-Caspase-3和Bax蛋白表达水平显著降低（P<0.05）。与NC抑制剂组相比，miR-126抑制剂组的miR-126表达水平、细胞增殖率、集落形成单位数量、迁移和侵袭能力以及Bcl-2蛋白表达水平显著降低（P<0.05），但细胞凋亡率、cleaved-Caspase-3和Bax蛋白表达水平显著升高（P<0.05）。
miR-126在DLBCL患者淋巴瘤组织中高表达，其表达水平与患者预后不良有关。miR-126可促进DLBCL细胞增殖、侵袭和迁移，并抑制细胞凋亡。
